NCT06392841 2025-10-20
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
Clinical Trials
13 trialsNCT06527690 2025-09-29
REPRESENTATION
Latin American Cooperative Oncology Group
Phase 2 Withdrawn
NCT06329830 2024-09-19
LUNAAR
Baptist Health South Florida
Phase 1/2 Withdrawn
NCT04296578 2021-08-12
Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone
Stanford University
Phase 1 Withdrawn
NCT02182622 2019-06-19
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
Hackensack Meridian Health
Phase 1 Withdrawn
NCT02763761 2018-10-09
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT01087580 2017-03-03
Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT00598858 2016-12-08
2007-5904
University of California, Irvine
Phase 2 Withdrawn
NCT01692483 2015-12-02
Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Janssen Pharmaceutica
Withdrawn
NCT02159690 2015-01-26
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
Johns Hopkins University
Phase 2 Withdrawn
NCT01750866 2013-10-16
Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01478308 2013-03-06
Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer
New Mexico Cancer Research Alliance
Phase 2 Withdrawn
NCT00811031 2012-07-30
Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn